# Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

> **NCT00989872** · PHASE1 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 67 (actual)

## Conditions studied

- Skin and Soft Tissue Infections
- Methicillin-resistant Staphylococcus Aureus

## Interventions

- **DRUG:** EDP-322

## Key facts

- **NCT ID:** NCT00989872
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2009-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989872, "Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00989872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*